SubsidieMeestersDevelopment of a first-in-class inhibitor of FIH for cancer immunotherapy
The project aims to valorise novel small molecule inhibitors of Factor Inhibiting HIF for lung cancer treatment by clarifying IP, engaging investors, and advancing drug candidate development.
Projectdetails
Introduction
We plan to carry out a valorisation project for a series of novel small molecule inhibitors of Factor Inhibiting HIF (FIH) that we have developed for the treatment of lung cancer, as a next-generation therapeutic approach in the field of immuno-oncology.
Valorisation Plan
The valorisation plan will include:
- Clarification of IP rights and strategy
- Establishing contacts with potential investors and pharma partners
- Verification of the potential for start-up creation
Lead Optimisation Campaign
Moreover, valorisation activities will include progression of hits against FIH into a lead optimisation campaign with the aim of designating a candidate drug.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-6-2022 |
| Einddatum | 30-11-2023 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIASpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Small molecule heparanase inhibitors as anti-metastatic cancer drugsThe Heparanib project aims to validate heparanase inhibitors as cancer treatments by synthesizing compounds, conducting PK/PD studies, and preparing for commercialization and spin-out. | ERC Proof of... | € 150.000 | 2023 | Details |
Novel macrodiolide ImmunosuppressantsThis project aims to develop novel macrocyclic immunosuppressants targeting IRF3 to address autoimmune and neuroinflammatory disorders, while securing IP and preparing for future investment. | ERC Proof of... | € 150.000 | 2025 | Details |
Targeted Immunocytokines by CaGing and local ReleaseThis project aims to develop and evaluate a novel, locally activated innate immune therapy for cancer that minimizes systemic toxicity while enhancing treatment efficacy. | ERC Proof of... | € 150.000 | 2025 | Details |
Targeting the Imidazoline I1 receptor as a novel treatment for AtherosclerosisImnovAth aims to develop a novel therapy targeting a microbiota-derived metabolite to enhance atherosclerosis treatment efficacy and advance towards clinical trials and commercialization. | ERC Proof of... | € 150.000 | 2024 | Details |
Novel engineered cytokines for human therapyDeveloping a novel protein design strategy for helix-bundle cytokines to enhance their therapeutic efficacy and safety, aiming to establish a start-up for commercialization. | ERC Proof of... | € 150.000 | 2022 | Details |
Small molecule heparanase inhibitors as anti-metastatic cancer drugs
The Heparanib project aims to validate heparanase inhibitors as cancer treatments by synthesizing compounds, conducting PK/PD studies, and preparing for commercialization and spin-out.
Novel macrodiolide Immunosuppressants
This project aims to develop novel macrocyclic immunosuppressants targeting IRF3 to address autoimmune and neuroinflammatory disorders, while securing IP and preparing for future investment.
Targeted Immunocytokines by CaGing and local Release
This project aims to develop and evaluate a novel, locally activated innate immune therapy for cancer that minimizes systemic toxicity while enhancing treatment efficacy.
Targeting the Imidazoline I1 receptor as a novel treatment for Atherosclerosis
ImnovAth aims to develop a novel therapy targeting a microbiota-derived metabolite to enhance atherosclerosis treatment efficacy and advance towards clinical trials and commercialization.
Novel engineered cytokines for human therapy
Developing a novel protein design strategy for helix-bundle cytokines to enhance their therapeutic efficacy and safety, aiming to establish a start-up for commercialization.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors. | EIC Accelerator | € 2.496.112 | 2024 | Details |
Targeting OGG1 in Idiopathic Pulmonary FibrosisThe TOPFIBRO project aims to advance OXC-201, a novel IPF treatment, through efficacy validation, safety assessments, and regulatory preparations for first-in-human studies, targeting a market launch. | EIC Transition | € 2.499.998 | 2023 | Details |
Pre-clinical validation and demonstration of PeptiCHIP: an immunopurification microfluidic device and software for (neo)antigen identification and prioritizationValo Therapeutics is developing PeptiCHIP, a microfluidic device and algorithm to efficiently identify neoantigens for personalized cancer immunotherapy, enhancing patient response rates. | EIC Transition | € 2.226.280 | 2023 | Details |
Development and validation of a pan-cancer neutrophil biomarker test for predicting clinical benefit from immunotherapy based on flow cytometry analysis of blood samplesThe NeutroFlow project aims to develop a non-invasive blood test using a flow cytometry assay to predict cancer immunotherapy benefits, enhancing patient outcomes and reducing costs. | EIC Transition | € 2.499.999 | 2025 | Details |
Photoacoustic imaging and artificial intelligence-based theranostic approach for cancerPHIRE aims to develop a novel theranostic device for high-resolution imaging and treatment of bladder cancer lesions under 1 mm, improving patient outcomes and reducing tumor relapse. | EIC Transition | € 2.084.871 | 2023 | Details |
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.
The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors.
Targeting OGG1 in Idiopathic Pulmonary Fibrosis
The TOPFIBRO project aims to advance OXC-201, a novel IPF treatment, through efficacy validation, safety assessments, and regulatory preparations for first-in-human studies, targeting a market launch.
Pre-clinical validation and demonstration of PeptiCHIP: an immunopurification microfluidic device and software for (neo)antigen identification and prioritization
Valo Therapeutics is developing PeptiCHIP, a microfluidic device and algorithm to efficiently identify neoantigens for personalized cancer immunotherapy, enhancing patient response rates.
Development and validation of a pan-cancer neutrophil biomarker test for predicting clinical benefit from immunotherapy based on flow cytometry analysis of blood samples
The NeutroFlow project aims to develop a non-invasive blood test using a flow cytometry assay to predict cancer immunotherapy benefits, enhancing patient outcomes and reducing costs.
Photoacoustic imaging and artificial intelligence-based theranostic approach for cancer
PHIRE aims to develop a novel theranostic device for high-resolution imaging and treatment of bladder cancer lesions under 1 mm, improving patient outcomes and reducing tumor relapse.